GLP-1 Therapies Beyond Obesity and the Ethics of Brain Data in Neurotech I E PISODE

Overview

The Science podcast episode from November 5, 2026 presents two main threads. First, an investigative report on consumer brain data collected by head-mounted neurotech wearables and the ethical implications of data sharing and AI training. Second, a discussion of a special issue on GLP-1 receptor agonists and metabolism that extends beyond obesity to cognition, cancer, and addiction. The episode features journalist Jonathan Moens, science editor Yevgenia Nusinovich, and NIH researcher Nora Volkoff, with host Sarah Crespi guiding the conversations.

Key insights

• Consumer neurotech can capture brain data that may be used to train foundation models, raising privacy and consent concerns.
• Privacy policies often lack detail on data transfer, third-party sharing, and de-identification, prompting calls for stronger standards.
• GLP-1 drugs, while established for obesity, are being explored for broader metabolic and non-metabolic effects including cognition and cancer prevention.
• Nora Volkoff discusses GLP-1 therapies as a potential route to more comprehensive addiction treatment, emphasizing the body-brain interaction and stigma reduction.

Introduction and framing

In this Science podcast, host Sarah Crespi introduces two intertwined topics centered on metabolism, brain health, and the ethics of emerging neurotechnologies. The first feature investigates the burgeoning consumer neurotechnology industry, focusing on head mounted devices that track brain activity and the privacy implications of such data. The second segment loops in a science editor and two researchers who contribute to a special issue on GLP-1 receptor agonists. The discussions illuminate how GLP-1–targeting therapies are expanding beyond obesity to cognitive function, cancer, and addiction, and what this means for clinical practice, policy, and patient care.

Brain data ethics in consumer neurotechnology

The investigative piece by Jonathan Moens centers on the relatively new market for consumer EEG wearables. These devices, often with four to six scalp sensors, sit above the skin rather than in clinical settings. The questions revolve around what data is collected, how it is used, and who can access or monetize it. Moens analyzed privacy policies across multiple devices to extract variables such as whether data can be transferred to other companies, sold to third parties, identified or linked back to individuals, and how data is stored or processed. The portraits he paints show a regulatory landscape with limited detail, leaving users vulnerable to opaque data practices. The interviewees note that while some wearables have robust scientific backing, a broader swath of products may not be grounded in rigorous validation, increasing the risk of overclaiming benefits about brain data readings.

Moens discusses the potential for brain data to be de-identified yet still reveal sensitive information when layered with other data types such as social media or personal identifiers. Experts warn that even superficial EEG data can, in an era of advanced AI, be decoded to infer inner speech, emotions, or cognitive states. The concept of brain foundation models—AI systems trained largely on neural data—emerges as a powerful but ethically fraught frontier. Companies in the space reveal that a large share of their data could be used to train these models, sometimes beyond what is disclosed in privacy policies. The discussion also touches on regulatory gaps in the United States and examples from China, where helmet-based fatigue detection could link brain data to workforce safety and even to enforcement mechanisms in some contexts.

GLP-1 therapies expanding beyond metabolism

Yevgenia Nusinovich, a science editor at Science, explains the rationale for a special issue devoted to GLP-1 receptor agonists and their broader health implications. The issue explores topics such as adipose tissue remodeling, diverse drug targets beyond GLP-1 receptors, the cognitive effects of GLP-1 therapies, and potential links to cancer prevention. The discussion emphasizes that GLP-1–targeted treatments can influence various organ systems and metabolic pathways, illustrating a holistic approach to metabolic health. The issue also examines policy and economic considerations, including affordability and access in different countries, which shape how these therapies are deployed globally. Nusinovich clarifies that while GLP-1 drugs have achieved blockbuster status for obesity, their broader uses require careful evaluation of efficacy, safety, and collaboration across therapeutic areas.

GLP-1 therapies and addiction: a whole-person perspective

In a follow-up interview, Nora Volkoff, director of the National Institute on Drug Abuse at NIH, discusses GLP-1–based therapies as a potential road to a holistic treatment for addiction. Volkoff explains the brain’s dopamine-based reward circuits and how GLP-1 receptors modulate this system, which may influence cravings and consumption of several substances. The conversation pushes beyond the brain to highlight the body’s metabolic state, inflammation, vascular health, cognition, and comorbidities such as obesity and diabetes that elevate addiction risk. Volkoff stresses the need to view addiction as a disease with biological underpinnings and suggests GLP-1 therapies could reduce stigma by integrating addiction treatment into mainstream medical practice. Open questions include optimal dosing, patient selection, and the risk of adverse effects such as thiamine deficiency-related issues when combined with alcohol use disorders.

Concluding notes

The podcast closes with acknowledgments of the contributors and a summary of the broader themes: the ethical use of brain data, the evolving landscape of GLP-1–targeted therapies, and the potential for GLP-1 drugs to impact addiction treatment and metabolic health in a comprehensive manner. The episode underscores the importance of robust privacy practices, transparent data policies, and careful, evidence-based translation of GLP-1 research into clinical care and public health policy.

Takeaways for researchers and listeners

• Brain data collected by consumer neurotech has powerful implications for AI and medicine; privacy protections must keep pace with capabilities.
• GLP-1 therapies hold promise for a range of conditions but require rigorous evaluation of dosing, patient populations, and long-term outcomes.
• A holistic, body-wide view of metabolism, inflammation, and cognition may be essential to advancing addiction treatment.
• Policy and affordability considerations will influence how these advances reach patients worldwide.